Vascular endothelial growth factor stimulates protein kinase CβII expression in chronic lymphocytic leukemia cells

Blood

Volumn 115, Issue 22, 2010, Pages 4447-4454

  Abrams, Simon T ^a   Brown, Benjamin R B ^a   Zuzel, Mirko ^a   Slupsky, Joseph R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; LY 379196; MITHRAMYCIN; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA 1; PROTEIN KINASE C BETA 2; UNCLASSIFIED DRUG; VASCULOTROPIN; 5,21 - 12,17-DIMETHENEO-18H-DIBENZO(I,O)PYRROLO(3,4-1)(1,8)DIAZACYCLOHEXANDECINE-18,10(19H)DIONE,8((DIMETHYLAMINO)METHYL)-6,7,8,9,10,11-HEXAHYDRO,MONOMETHANESULFONATE; 5,21 12,17 DIMETHENEO 18H DIBENZO(I,O)PYRROLO(3,4 1)(1,8)DIAZACYCLOHEXANDECINE 18,10(19H)DIONE,8((DIMETHYLAMINO)METHYL) 6,7,8,9,10,11 HEXAHYDRO,MONOMETHANESULFONATE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; MESSENGER RNA; MESYLIC ACID DERIVATIVE; PRIMER DNA; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; RECOMBINANT PROTEIN; RNA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; CELL STIMULATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IN VITRO STUDY; METABOLISM; NUCLEOTIDE SEQUENCE; PROMOTER REGION;

BASE SEQUENCE; DNA PRIMERS; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MESYLATES; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953930920     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-229872     Document Type: Article

References (55)

1. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029.
2. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003;21:841-894.
3. Abrams ST, Lakum T, Lin K, et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood. 2007;109(3):1193-1201.
4. Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem. 1995;270(48):28495-28498.
5. Kang SW, Wahl MI, Chu J, et al. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J. 2001;20(20):5692-5702.
6. Su TT, Guo B, Kawakami Y, et al. PKC-b controls IkB kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol. 2002;3(8):780-786.
7. Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase Cbeta-deficient mice. Science. 1996;273:788-791.
8. Holler C, Pinon JD, Denk U, et al. PKCb is essential for the development of CLL in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in CLL. Blood. 2009;113(12):2791-2794.
9. Greenham J, Adams M, Doggett N, Mole S. Elucidation of the exon-intron structure and size of the human protein kinase C beta gene (PRKCB). Hum Genet. 1998;103(4):483-487.
10. Niino YS, Ohno S, Suzuki K. Positive and negative regulation of the transcription of the human protein kinase C beta gene. J Biol Chem. 1992;267(9):6158-6163.
11. Obeid LM, Blobe GC, Karolak LA, Hannun YA. Cloning and characterization of the major promoter of the human protein kinase C beta gene: regulation by phorbol esters. J Biol Chem. 1992;267(29):20804-20810.
12. Cejas PJ, Carlson LM, Zhang J, et al. Protein kinase C betaII plays an essential role in dendritic cell differentiation and autoregulates its own expression. J Biol Chem. 2005;280(31):28412-28423.
13. Liu Y, Su W, Thompson EA, Leitges M, Murray NR, Fields AP. Protein kinase CbetaII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J Biol Chem. 2004;279(44):45556-45563.
14. Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma. 2004;45(12):2365-2372.
15. Petlickovski A, Laurenti L, Li X, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005;105(12):4820-4827.
16. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1a. Blood. 2005;106(3):1012-1020.
17. Patke A, Mecklenbrauker I, Erdjument-Bromage H, Tempst P, Tarakhovsky A. BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. J Exp Med. 2006;203(11):2551-2562.
18. Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 2000;96(9):3181-3187.
19. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 2004;104(3):788-794.
20. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98(9):2018-2026.
21. Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 2005;19(4):524-530.
22. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia. 2005;19(4):513-523.
23. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
24. Lin K, Glenn MA, Harris RJ, et al. c-Abl expression in CLL cells: clinical and therapeutic implications. Cancer Res. 2006;66(15):7801-7809.
25. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260(6):3440-3450.
26. Komander D, Kular GS, Schuttelkopf AW, et al. Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. Structure. 2004;12(2):215-226.
27. Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-13-[(Dimethylamino) methyl]-10,11,14,15-tetrahydro-4,9: 16,21-dimetheno-1H,13H-dibenzo[e,k] pyrrolo[3,4-h] [1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cbeta. J Med Chem. 1996;39(14):2664-2671.
28. Zhang HC, Derian CK, McComsey DF, et al. Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety. J Med Chem. 2005;48(6):1725-1728.
29. Ray R, Snyder RC, Thomas S, Koller CA, Miller DM. Mithramycin blocks protein binding and function of the SV40 early promoter. J Clin Invest. 1989;83(6):2003-2007.
30. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med. 1992;176(5):1319-1326.
31. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon-gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med. 1993;177(1):213-218.
32. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001;97(9):2777-2783.
33. König A, Menzel T, Lynen S, et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia. 1997;11(2):258-265.
34. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971-979.
35. Giatromanolaki A, Koukourakis M, Pezzella F, et al. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol. 2008;26(4):219-224.
36. Gora-Tybor J, Blonski JZ, Robak T. Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. Eur Cytokine Netw. 2005;16(1):41-46.
37. Kay NE, Bone ND, Tschumper RC, et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia. 2002;16(5):911-919.
38. Zhen HY, Huang YH, Zhen YS. Lidamycin inhibits the cancer cell PKC activity induced by basic fibroblast growth factor. Yao Xue Xue Bao. 2005;40(12):1110-1115.
39. Yan J-C, Wu Z-G, Kong X-T, Zong R-Q, Zhan L-Z. Effect of CD40-CD40 ligand interaction on diacylglycerol-protein kinase C and inositol trisphosphate-Ca2+ signal transduction pathway in human umbilical vein endothelial cells. Clin Chim Acta. 2003;337(1):133-140.
40. Zhang X, Guo S, Lu K, et al. Different roles of PKC and PKA in effect of interferon-gamma on proliferation and collagen synthesis of fibroblasts. Acta Pharmacol Sin. 2004;25(10):1320-1326.
41. Ferrajoli A, Manshouri T, Estrov Z, et al. High levels of vascular endothelial growth factor receptor- 2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001;7(4):795-799.
42. Krejcí P, Dvoráková D, Krahulcová E, et al. FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. Leukemia. 2001;15(2):228-237.
43. Sutcliffe M, Oscier D, Wright DH. Syndecan-1 (CD138) expression in human non-Hodgkin's lymphomas. Br J Haematol. 2000;110(1):239-240.
44. Romanov VV, James CH, Sherrington PD, Pettitt AR. Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia. Oncogene. 2005;24(45):6855-6860.
45. Angeli V, Ginhoux F, Llodra J, et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity. 2006;24(2):203-215.
46. Pellet-Many C, Frankel P, Jia H, Zachary I. Neuropilins: structure, function and role in disease. Biochem J. 2008;411(2):211-226.
47. Mahajna J, King P, Parker P, Haley J. Autoregulation of cloned human protein kinase C beta and gamma gene promoters in U937 cells. DNA Cell Biol. 1995;14(3):213-222.
48. Wahlfors J, Hiltunen H, Heinonen K, Hamalainen E, Alhonen L, Janne J. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood. 1992;80(8):2074-2080.
49. Rush LJ, Raval A, Funchain P, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 2004;64(7):2424-2433.
50. Araki S-i, Ng DPK, Krolewski B, et al. Identification of a common risk haplotype for diabetic nephropathy at the protein kinase C-beta1 (PRKCB1) gene locus. J Am Soc Nephrol. 2003;14(8):2015-2024.
51. Langham R, Kelly D, Gow R, et al. Increased renal gene transcription of protein kinase C-β in human diabetic nephropathy: relationship to long-term glycaemic control. Diabetologia. 2008;51(4):668-674.
52. Osterhoff MA, Heuer S, Pfeiffer M, et al. Identification of a functional protein kinase Cbeta promoter polymorphism in humans related to insulin resistance. Mol Genet Metab. 2008;93(2):210-215.
53. Ikeda Y, Suehiro T, Osaki F, Tsuzura S, Kumon Y, Hashimoto K. Polymorphisms in the 5′-upstream region of the PKCbeta gene in Japanese patients with Type 2 diabetes. Diabet Med. 2004;21(10):1113-1120.
54. Gao T, Brognard J, Newton AC. The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem. 2008;283(10):6300-6311.
55. Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res. 2008;68(4):1012-1021.